Page 1

NeuroScientific Biopharmaceuticals Limited Appendix 4E Preliminary final report 1. Company details Name of entity : ABN : Reporting period : Previous period : NeuroScientific Biopharmaceuticals Limited 13 102 832 995 For the year ended 30 June 2021 For the year ended 30 June 2020 2. Results for announcement to the market Revenues from ordinary activities Loss from ordinary activities after tax attributable to the owners of NeuroScientific Biopharmaceuticals Limited Loss for the year attributable to the owners of NeuroScientific Biopharmaceuticals Limited Dividends Final dividend for the year ended 30 June 2020 Final dividend for the year ended 30 June 2021 3. Net tangible assets Net tangible assets per ordinary share 등등 등 4. Audit qualification or review The financial statements have been audited and an unqualified opinion has been issued . $ 1271 % to 1,045,874 10.8 % to ( 3,177,831 ) 10.8 % to ( 3,177,831 ) Franked Amount per amount per security security Cents Cents Nil Nil ZZ Nil Nil Reporting period Cents Previous period Cents 9.92 4.23 5. Attachments The Annual Report of NeuroScientific Biopharmaceuticals Limited for the year ended 30 June 2021 is attached .